Extrawell Pharmaceutical Holdings (HKSE:00858) Interest Expense : HK$-17.15 Mil (TTM As of Sep. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Extrawell Pharmaceutical Holdings's interest expense for the six months ended in Sep. 2023 was HK$ -9.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was HK$-17.15 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Extrawell Pharmaceutical Holdings's Operating Income for the six months ended in Sep. 2023 was HK$ -3.22 Mil. Extrawell Pharmaceutical Holdings's Interest Expense for the six months ended in Sep. 2023 was HK$ -9.02 Mil. Extrawell Pharmaceutical Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Extrawell Pharmaceutical Holdings Interest Expense Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Interest Expense Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-7.82

-9.35

-11.24

-13.23

-15.64

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Interest Expense	Get a 7-Day Free Trial															-6.36	-6.87	-7.50	-8.14	-9.02

Extrawell Pharmaceutical Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-17.15 Mil.

Extrawell Pharmaceutical Holdings (HKSE:00858) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Extrawell Pharmaceutical Holdings's Interest Expense for the six months ended in Sep. 2023 was HK$-9.02 Mil. Its Operating Income for the six months ended in Sep. 2023 was HK$-3.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2023 was HK$110.02 Mil.

Extrawell Pharmaceutical Holdings's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Extrawell Pharmaceutical Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines